idarubicin hydrochloride / Generic mfg. - LARVOL DELTA

Update AML: Updated disease monitoring and treatment to enhance outcomes for pediatric AML (NCT07059975) (ASH 2025) - P1 | "These patients will receive the common salvage regimen Idarubicin-fludarabine-cytarabine (IdaFLA) as the second cycle (Induction 2) in lieu of standard DA8 (Daunorubicin-Cytarabine) chemotherapy...In UPDATE AML, IR patients will receive VIA in place of MA (mitoxantrone-cytarabine) to eliminate exposure to the cardiotoxic agent mitoxantrone. HR patients will receive VIA as Intensification 1 prior to SCT, in place of the genotoxic agent etoposide and to provide venetoclax exposure prior to SCT...All newly diagnosed patients at TXCH >1 month to <30 years old with non-FLT3-ITD+ AML will be eligible for enrollment after completing standard Induction 1 chemotherapy consisting of combination of daunorubicin and cytarabine +/- gemtuzumab...Over 3 years, the study is anticipated to accrue 36-40 patients and generate important feasibility data for our treatment and molecular MRD innovations. Our results will inform future cooperative group trials with respect to..."

Clinical • IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Pediatrics • FLT3

Venetoclax-based salvage therapy achieves high remission rates after 7+3 or low-dose cytarabine (ASH 2025) - "Introduction: In the Brazilian public health system (SUS), salvage chemotherapy for fit patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) after standard 7+3 induction (7 days of cytarabine plus 3 days of an anthracycline) is usually FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor [G-CSF], and idarubicin) or MEC (mitoxantrone, etoposide, and cytarabine)...Although the venetoclax–cytarabine (VEN-ARAC) or venetoclax–azacitidine (VEN-AZA) combination is approved as first-line therapy for unfit patients, it is generally not available in SUS... In this real-world study, VEN-based salvage therapy induced rapid and high CR rates after 7+3 or LDAC, with a favorable safety profile, and may serve as a less-toxic bridge to allo-HSCT."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia

FLT3 testing and guideline concordance in Acute Myeloid Leukemia across an Indiana health system (ASH 2025) - "Current guidelines recommend FLT3 mutation testing at diagnosis to inform risk stratification and guide the use of FLT3 inhibitors such as midostaurin, quizartinib, and gilteritinib...The most frequently used induction therapies included venetoclax in combination with a hypomethylating agent (30%), 7+3 (15.7%), and a combination regimen consisting of fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor (FLAG IDA; 13.8%)... FLT3 testing was commonly performed in this cohort, yet notable variability in guideline adherence was observed. Guideline-concordant induction regimen selection was marginally higher for patients with FLT3 mutations. These findings underscore the need for institutional quality improvement initiatives aimed at enhancing the documentation of FLT3 status and optimizing the integration of guideline-directed therapies in AML management."

Discordant • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • FLT3

Adult acute myeloid leukaemia with DDX3X::MLLT10: A rare entity with significant unmet clinical needs (ASH 2025) - "She commenced salvage fludarabine, cytarabine, idarubicin and filgrastim (FLAG-Ida) therapy with BME on day 34 of treatment showing morphologic leukaemia-free state (MLFS)...She then commenced bridging venetoclax/azacitidine (Ven/Aza) therapy with a plan for allogeneic haematopoietic stem cell transplant...However, more data are required for further characterisation. These findings may inform future iterations of AML classification and prognostication (e.g., WHO) in adults."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Cerebral Hemorrhage • Hematological Malignancies • Infectious Disease • Leukemia • Respiratory Diseases • Septic Shock • T Acute Lymphoblastic Leukemia • CEBPA • DDX3X • FLT3 • JAK2 • KMT2A • KRAS • MLLT10 • NPM1 • SH2B3 • SMARCA4

Inhibition of FSP1 enhances venetoclax induced cell death in Acute Myeloid Leukemia by the ferroptosis pathway (ASH 2025) - "Methods AML cell lines THP-1 and Kasumi-1 were treated with idarubicin (IDA), venetoclax, the ferroptosis inducer RSL3, the inhibitor Ferrostatin-1, and the ferroptosis suppressor protein 1 (FSP1) inhibitor iFSP1. FSP1 inhibition increased the sensitivity of AML cells to venetoclax via the ferroptosis pathway. iFSP1 in combination with venetoclax may provide a favorable strategy for AML treatment."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • AIFM2 • ATG7 • BCL2 • GPX4 • MYCN • PACERR • PTGS2 • SLC7A11 • TLR4

Prospective clinical study on the efficacy and safety of the DCIA±X regimen in treating relapsed/refractory acute myeloid leukemia (ASH 2025) - "The DCIA±X regimen—combining decitabine, cladribine, idarubicin, cytarabine, and optional targeted agents (X)—leverages synergistic mechanisms to overcome chemoresistance. This novel reinduction regimen demonstrated robust activity and acceptable toxicity in treating R/R AML patients, achieving high CR/CRi and ORR rates, facilitating successful bridge to transplant in most responders, and promising 1-year RFS and OS."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia

The efficacy and safety of venetoclax and azacitidine combined with granulocyte-colony stimulating factor in the treatment of Acute Myeloid Leukemia (ASH 2025) - "Objective This study was designed to evaluate the efficacy and safety of the azacitidine-venetoclax-G-CSF (VAG) combination regimen compared with a control regimen of idarubicin-cytarabine in newly diagnosed patients with acute myeloid leukemia (AML). This suggests that the VAG regimen offers a promising treatment option for both young and elderly patients with ND-AML. Key words Acute myeloid leukemia; Venetoclax; Azacitidine; Granulocyte-Colony Stimulating Factor;"

Acute Myelogenous Leukemia • Febrile Neutropenia • Neutropenia • Thrombocytopenia • ASXL1 • BCOR • CEBPA • DNMT3A • FLT3 • KRAS • NPM1 • NRAS • RUNX1 • SRSF2 • STAG2 • TET2

Comparative long-term cardiovascular and hematologic outcomes of gemtuzumab ozogamicin containing regimens versus idarubicin containing regimens in acute promyelocytic leukemia: A propensity-matched analysis of real-world multicenter data (ASH 2025) - "Conclusions In this real-world, propensity-matched analysis of APL patients, ATRA + GO was associated with significantly lower 5-year mortality and incidence of cardiac arrest but increased risks of DIC compared to ATRA + idarubicin. These findings highlight the importance of individualized risk-benefit assessment when selecting induction regimens for APL."

Clinical • Real-world • Real-world evidence • Acute Promyelocytic Leukemia • Asthma • Atrial Fibrillation • Congestive Heart Failure • Diabetes • Endocrine Disorders • Heart Failure • Hematological Malignancies • Hypertension • Immunology • Ischemic stroke • Leukemia • Metabolic Disorders • Pulmonary Disease • Respiratory Diseases • Thrombosis • CD33

Clia plus venetoclax for AML: Feasibility and efficacy in a hybrid community setting (ASH 2025) - "Induction consisted of cladribine 5 mg/m 2 IV (days 1-5), cytarabine 1-1.5 g/m 2 IV (days 1-5), and idarubicin 10 mg/m 2 IV (days 1-3), and venetoclax 400 mg PO (days 2-8; dose-adjusted for azole use). CLIA-VEN was well tolerated and yielded high MRD-negative remission rates in a hybrid community oncology setting, with encouraging survival outcomes and successful bridging to alloSCT. The absence of TRM and the high proportion of patients achieving MRD negativity mirror outcomes reported in academic phase 2 studies, suggesting that such results are achievable outside specialized tertiary centers. These findings underscore the feasibility of implementing intensive VEN-based regimens in hybrid community practices, where logistical constraints and patient demographics may differ from those in trial populations."

Clinical • Acute Myelogenous Leukemia • Febrile Neutropenia • Infectious Disease • Myelodysplastic Syndrome • Neutropenia • DNMT3A • FLT3 • IDH1 • KMT2A • NPM1

CHG combined with venetoclax and azacytidine as induction chemotherapy in acute myeloid leukemia (ASH 2025) - P2 | "Based on this premise, we endeavored to develop a low-dose, long-course CHG regimen (cytarabine, homoharringtonine, and granulocyte stimulating factor) in combination with the demethylating agent azacytidine and the Bcl-2 inhibitor venetoclax as an induction regimen(NCT06470841)...One patient achieved CRi after receiving daunorubicin plus cytarabine (DA) induction chemotherapy. However, the patient relapsed after completing 2 courses of consolidation chemotherapy (1 course of DA and 1 course of venetoclax + azacytidine + sorafenib)...In another patient, non-response (NR) was observed after 1 course of idarubicin plus cytarabine... In this trial, we utilized a low-dose, long-course regimen of CHG in combination with the demethylating drug azacytidine and the Bcl-2 inhibitor venetoclax as an induction regimen. Notably, all 5 patients achieved complete remission by a single course of VACHG induction chemotherapy, and the combined chemotherapy regimen demonstrated..."

Acute Kidney Injury • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Nephrology • Renal Disease

Combination of mitoxantrone hydrochloride liposome with CLAG regimen in patients with relapsed or refractory Acute Myeloid Leukemia: A prospective, single-arm study (ASH 2025) - P4 | "The CLAG ± M/I regimen [cladribine, cytarabine, granulocyte colony-stimulating factor (G-CSF) ± mitoxantrone or idarubicin] is a common utilized chemotherapy regimen. Lipo-MIT combined with CLAG regimen showed a promising efficacy and manageable safety in R/R AML. The favorable post-transplant survival suggests this regimen is effective to bridge R/R AML patients to HSCT. The trial is still ongoing."

Clinical • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Bone Marrow Transplantation • Colorectal Cancer • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Neutropenia • Thrombocytopenia • ASXL1 • CEBPA • FLT3 • TP53 • U2AF1

A diagnostic pitfall: Therapy-related acute promyelocytic leukemia mimicking mixed-phenotype acute leukemia (ASH 2025) - "The BC was treated according to national guidelines with surgery, radiation therapy, chemotherapy (4 cycles of etoposide and cyclophosphamide and 12 cycles of paclitaxel), and endocrine maintenance therapy and has been in remission ever since...Induction therapy was immediately initiated according to the current APL treatment standard with tretinoin (ATRA) and arsenic trioxide (ATO) plus a single dose of idarubicin based on the APOLLO study for cytoreduction because the patient developed hyperleukocytosis mainly due to administration of corticosteroids...(II.) Even in the context of previous chemotherapy, genetic testing is mandatory as t-APL is treated specifically and shows a better prognosis than other forms of therapy-related AML. (III.) It highlights the importance of careful integrated diagnostics for acute leukemias that incorporate morphology, flow cytometry, and genetic results to guide therapeutic decision-making."

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Breast Cancer • Gene Therapies • Hematological Malignancies • Leukemia • Solid Tumor

Reduced intensive chemotherapy combined with venetoclax in adult patients with Acute Myeloid Leukemia: A retrospective single-center analysis (ASH 2025) - "Methods A retrospective single-center analysis was conducted on 36 adult AML patients (≤65 years) treated with reduced intensiveIA (almost half dosage of 3+7 regimen)+ VEN (idarubicin 6 mg/m² on days 1–3, cytarabine 60 mg/m² on days 1–5, venetoclax 100 mg daily with voriconazole 200 mg q12h). Reduced intensive IA + VEN demonstrated efficacy comparable to that of standard regimen DA+VEN, but with reduced toxicity, especially lower cardiac toxicity, which would be benefit for long term survival in AML adult patients.Conclusion The reduced intensive IA + VEN regimen achieved high ORR and durable remissions in adult AML patients, including those with high-risk disease. This approach offers a promising strategy to improve outcomes in AML while reducing toxicity."

Retrospective data • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia

Experience of management of patients with acute promyelocytic leukemia (APL) in Armenia. (ASH 2025) - "The main part of adult patients independent of risk group (n=22) received treatment with ATRA+ATO regimen, 3pts with (7+3) +ATRA, 1 patient with ATRA+ Idarubicin, 2 high risk pts with APML-4, 5 patients did not receive antileukemic treatment, 5 pediatric patients received treatment with APL-BFM 2013 and PETHAEM/HOV 2005+ATRA.Thirty patients experienced complete remission (CR)...Implementing routine qPCR testing for MRD in APL patients is a critical step to improve disease monitoring and long-term outcomes. Enhanced early detection and comprehensive supportive care strategies are essential for improving survival rates among APL patients in Armenia."

Clinical • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • PML

Association of combined IKZF1plus genotype and ABL1 mutations with outcomes in adult BCR::ABL1-positive acute lymphoblastic leukemia (ASH 2025) - P=N/A | "The patients received a TKI-based [imatinib or flumatinib (a second-generation TKI)] standardized VIP regimen (Vincristine/Idarubicin/Prednisone), and eligible patients were recommended to undergo allo-HSCT. Notably, IKZF1 plus patients harboring T315I mutation constitute a subgroup with dismal survival, likely associated with the down-regulation of p53 pathways, and they would benefit from allo-HSCT. Conversely, IKZF1 plus cases without ABL1 mutations exhibit a markedly favorable prognosis."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • ABL1 • IKZF1

PPP1R15A as a therapeutic target to overcome chemoresistance in AML: An in vitro study (ASH 2025) - "Then guanabenz was selected for combination studies with idarubicin(IC₅₀: 10 nM, MOLM-13; 1 nM , KASUMI-1) or cytarabine (100 nM)...Only guanabenz instead of sephin-1 led to decreased levels of cytotoxicity... Our findings identify PPP1R15A as a stress-adaptive regulator of chemoresistance in AML. Its depletion—either genetically or pharmacologically—rewires the DDR, disrupts mitochondrial and proteostasis networks, and amplifies apoptotic signaling upon chemotherapy. Targeting PPP1R15A sensitizes AML cells to genotoxic stress and represents a promising combinatorial strategy to overcome drug resistance and improve therapeutic efficacy."

Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Metabolic Disorders • CASP3 • CD24 • DDIT4 • EEF1A1 • PPP1R15A

Dichotomy of TP53 mutant AML MRD microenvironment: Spatially segregated immunosuppressive mechanisms and niche-specific structural support (ASH 2025) - "Patients received either Aza/Ven- or Ara-C/Idarubicin-based regimens combined with magrolimab or gilteritinib. single-cell proteomics analysis of bone marrow biopsies provides a spatially resolved view of the TP53mut AML microenvironment, uncovering persistent p53+ MRD cells enriched for erythroid phenotypes. Their structural niches suggest MRD-protective roles of MSCs and adipocytes, and immunosuppressive features such as spatial separation between T-cell clusters and p53+ cells, involvement of Tregs within lymphocyte clusters and a distance-dependent TIGIT surge of T and NK-cells in proximity to p53+ cells. This comprehensive spatial analysis offers new insights into the mechanisms of immune escape and MRD persistence in TP53mut AML."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • CD14 • CD34 • FOXP3 • NPM1 • TFRC • TIGIT • TP53

Sequential therapy with fitcy preparative regimen for patients above the age of 70 years with active AML – a single center retrospective analysis (ASH 2025) - "Given the limited efficacy of salvage chemotherapy in this population and the low likelihoodof long-term survival, we adopted a modified reduced-intensity conditioning (RIC) regimen—FITCy(fludarabine, cytarabine ± idarubicin, and cyclophosphamide with 4 Gy total body irradiation)—in elderlypatients with available donors, aiming to proceed directly to allogeneic hematopoietic cell transplantation(HCT) despite active disease.Methods – All patients who were diagnosed with AML and were above the age of 70 years, were identifiedby the transplantation coordinator nurse and underwent donor evaluation within 2 days from diagnosis.Patients treated with 7+3 or venetoclax-azacitidine underwent bone marrow assessment on day 14 orday 21, respectively. Improved GVHD prophylaxis and early referral (primary vs. relapse setting) were associated withbetter GRFS and OS. Age alone should not be a barrier to this strategy, though it must be weighedagainst emerging targeted therapies."

Retrospective data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Mucositis • Transplant Rejection

Autologous hematopoietic stem cell transplantation followed by CD19/CD22 dual-target CAR-T therapy for refractory or relapsed burkitt lymphoma (ASH 2025) - P=N/A | "The initial ASCTregimen was BEAM until 2022; it was then modified to Be+IDA+FLU+Ara-C+melphalan (BIFAM)...One month post-infusion of CAR-T cells,maintenance therapy with a CD20 monoclonal antibody and chidamide (an histone deacetylaseinhibitors, HDACi) was initiated.There were 9 males and 4 females, with a median age of 29 years (range: 4 to 44)...Subgroup analyses indicated that there were no significantdifferences in 2-year OS and PFS based on the presence of large masses versus their absence (57.1% vs.80%), bone marrow ±CNS involvement (53.3% vs. 71.4%), TP53 abnormalities (71.4% vs. 50%), bridgingtherapy with radiotherapy versus without it (71.4% vs. 53.3%), BEAM versus BIFAM regimens (66.7% vs.66.7%) (all p>0.05).ConclusionThis clinical trial confirmed the efficacy and safety of ASCT followed by CD19/CD22 CAR-T therapy for R/RBurkitt lymphoma, demonstrating a 2-year OS rate of 65.6% and a 2-year PFS rate of 56.3%...There were 9 males and 4 females,..."

IO biomarker • B Cell Lymphoma • Bone Marrow Transplantation • Burkitt Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation • CD22 • TP53

Blinatumomab combined with low-dose chemotherapy and TKI as first-line induction for newly diagnosed ph+ b-ALL: Improved efficacy and reduced toxicity (ASH 2025) - "Conventional Chemotherapy Group: Received the VICP regimen (vincristine 2 mg IV days 1, 8, 15, 22; idarubicin 8 mg/m² IV days 1-3; cyclophosphamide 750 mg/m² IV day 1; prednisone 1 mg/kg/daydays 1-28) with TKI.Following achievement of complete remission (CR) in both treatment groups, subsequent therapy phases(consolidation, maintenance, and central nervous system prophylaxis) were uniformly administeredaccording to the Chinese Adult Lymphoblastic Leukemia Collaborative Group 2008 protocol (CALLG2008).The primary endpoint was MRD negativity rate; secondary endpoints included progression-free survival(PFS), overall survival (OS), relapse rate and safety. The median age was 51.1 years in the blinatumomab group (n=11) and 42.6 years in theconventional chemotherapy group (n=13). The median age was 51.1 years in the blinatumomab group (n=11) and 42.6 years in theconventional chemotherapy group (n=13). All 24 patients attained CR after one cycle of..."

Clinical • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • ABL1 • BCR

Acute leukemia during pregnancy: A three-decade Mayo Clinic experience (ASH 2025) - "One patient had refractory disease and achieved partial remission after salvage,another had refractory disease and achieved CR after multiple lines of therapy, and a third achieved CRafter FLAG-idarubicin and revumenib...All receivedintensive induction: 7+3 (n=5), 7+3 + ATRA (n=1), 7+3 + gilteritinib (n=1), and 7+3 + nilotinib (n=1)...Notably, 5 (28%) of patients received chemotherapy during pregnancy. Larger,multi-institutional cohorts are warranted to further characterize the incidence and outcomes of AL inpregnancy."

Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Leukemia • Lymphoma • Pneumonia • Respiratory Diseases • T Acute Lymphoblastic Leukemia • KMT2A • NUP214

Quantitative ex vivo synergy profiling uncovers heterogeneous combination responses in AML primary samples (ASH 2025) - "Cells were seeded into 384-well plates and exposed to variousconcentrations of five drug pairs—two venetoclax (VEN)-based (VEN+decitabine, or VEN+azacitidine) andthree cytarabine (CYT)-based (CYT+daunorubicin, CYT+mitoxantrone, or CYT+idarubicin). In three patients, synergy was comparably high for both VEN- and CYT-basedpairs, whereas another three exhibited uniformly low synergy across all combinations. These findingsunderscore the potential of ex vivo synergy profiling to stratify AML patients for individualizedcombination therapy selection."

Heterogeneity • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • CD20

Mitoxantrone liposome plus cytarabine and azacitidine for newly diagnosed Acute Myeloid Leukemia: A prospective, multicenter, randomized controlled study (ASH 2025) - P3 | "daunorubicin or idarubicin, with the antimetabolitecytarabine—often known as the 7+3 regimen—which results in a complete remission (CR) rate of roughly60%. No treatment-related deaths were reported.Conclusion The MA+AZA regimen shows encouraging efficacy and manageable toxicity in newlydiagnosed AML. Preliminary efficacy was observed, with ongoing sample size expansion and follow-upextension to evaluate long-term survival outcomes"

Clinical • Acute Myelogenous Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Thrombocytopenia • CD34

Multicenter prospective Phase II study of decitabine priming combined with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed Acute Myeloid Leukemia (ASH 2025) - "These results support DP-IAG as an effective and tolerable salvage regimen, providing afeasible bridge to HSCT and a new reference point for future trials in pediatric R/R AML."

Clinical • P2 data • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Infectious Disease

Rapid bone marrow blast reduction-guided selinexor-based regimen therapy in relapsed/refractory and newly diagnosed acute myeloid leukemia (ASH 2025) - "All received the XAB regimen: selinexor (35 mg/m² twice weekly), azacitidine (75mg/m²/day days 1–5), and venetoclax (100mg day 1, 200mg day 2, and 400 mg daily days 3- 21)...These early responders continued XAB for a second week, with all 8 (100%) maintainingCR/CRi; transplant-eligible patients will proceed to two cycles of consolidation (X + Ara-C +idarubicin/mitoxantrone) followed by allo-HCST The remaining 13 patients (61.9%) with PR/NR at week 1received XAB + A50 during week 2... Bone marrow blast reduction kinetics (Types A-D) robustly predict therapeutic efficacy of theXAB regimen across AML disease states. In R/R AML, Type A kinetics identify patients benefiting fromcontinued XAB (100% CR/CRi). In ND AML, this regimen achieves 100% CR/CRi in rapid responders."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia